Disease or Syndrome – Page 16

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market

Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition

2 months ago talkbio0Tagged Camzyos, Clinical Trials, Hypertrophic Cardiomyopathy, Hypertrophic cardiomyopathy without obstruction, Myers, Obstructed

Camzyos, Hypertrophic Cardiomyopathy, Myers, Hypertrophic cardiomyopathy without obstruction, Obstructed, Clinical Trials

Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly

2 months ago talkbio0Tagged Alzheimer, Apolipoprotein E4, ARIA, authorization, Biogen, Eisai, Eli Lilly, EU, High, Kisunla, Leqembi, Restricted

Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High

Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack

2 months ago talkbio0Tagged B-Lymphocytes, Boehringer, CUE-501, Cues, Depletion, paying, T-Lymphocyte

Cues, CUE-501, B-Lymphocytes, Boehringer, Depletion, paying, T-Lymphocyte

Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.

2 months ago talkbio0Tagged amgen, Approved, Biological Factors, Biosimilars, competition, Enbrel, Erelzi, etanercept, Legal patent, Market, Rheumatoid Arthritis, sandoz, United States, United States Food and Drug Administration

Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.

Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335

2 months ago talkbio0Tagged biopharma exit strategy, Chronic Spontaneous Urticaria, clinical-stage, CSU, drug sales, Inhibitor, KIT, Kit device, shareholder, THB335, Third Harmonic Bio liquidation, value maximization

Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization

Ironwood Pharmaceuticals’ Stock Plummets Following Layoffs and FDA Setback for Apraglutide

2 months ago talkbio0Tagged Biotechnology, Goldman Sachs, Ironwood, Phase 3 Clinical Trials, plunge, regulatory hurdle, Short Bowel Syndrome, strategic alternatives, United States Food and Drug Administration

Ironwood Pharmaceuticals , apraglutide , short bowel syndrome (SBS) , Phase III trial , layoffs , FDA regulatory hurdle , stock plunge , strategic alternatives , Goldman Sachs , biotechnology